FDA Extends Quizartinib NDA Review for Newly Diagnosed FLT3-ITD Positive AML Patients: A Heartfelt Update
FDA Extends Quizartinib NDA Review for Newly Diagnosed FLT3-ITD Positive AML Patients: A Heartfelt Update A Personal Reflection As someone who has been personally affected by Acute Myeloid Leukemia (AML), the news of the FDA extending the review period for quizartinib is both hopeful and bittersweet. I have seen firsthand the toll that this aggressive…